Patients Already in Biohaven Epilepsy Trials Keep Dosing as FDA Pauses New Enrollment Over a Rodent Finding
Biohaven's epilepsy drug trials paused by FDA due to rodent study findings. New enrollments halted, but current patients continue dosing. Biohaven shares fell over 10% post-announcement. The company expects new animal data soon and maintains the drug has been safe in over 1,200 participants. Top-line results from one study are still expected in 2H 2026.
How this was made
The 30-second read
Why it matters
The regulatory hold introduces uncertainty on trial timelines and may delay FDA submission, pressuring the stock.
Market read
Regulatory hold is a material negative catalyst for Biohaven and could affect peer biotech valuations.
What to watch
Potential upside from the pending licensing deal with SK Biopharma and existing trial data showing safety.
Background
Biohaven's opakalim (BHV‑7000) is in late‑stage epilepsy trials; a recent FDA partial hold pauses new enrollment due to a rodent metabolite finding.
Ticker impact
FDA placed a partial clinical hold on Biohaven's opakalim epilepsy trials, pausing new patient enrollment.
downward pressure, potential 5‑10% decline in the short term
Regulatory hold is a material negative catalyst for a late‑stage biotech; market typically reacts negatively to enrollment pauses.
Market effects
May weigh on other epilepsy‑focused biotech stocks and broader neuro‑pharma sector.
US biotech market could see modest sell‑off; limited impact outside the sector.
Limited to investors tracking FDA actions on late‑stage drug candidates.
Counterpoint
If the animal data prove non‑translatable, the hold could be lifted quickly, limiting downside.
Key entities
- companyBiohaven Pharmaceutical
US‑listed biotech developing opakalim for refractory focal epilepsy.
- companySK Biopharmaceuticals
South Korean partner in licensing deal for Biohaven's Kv7 platform.
